HUP0303199A2 - Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására - Google Patents

Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására

Info

Publication number
HUP0303199A2
HUP0303199A2 HU0303199A HUP0303199A HUP0303199A2 HU P0303199 A2 HUP0303199 A2 HU P0303199A2 HU 0303199 A HU0303199 A HU 0303199A HU P0303199 A HUP0303199 A HU P0303199A HU P0303199 A2 HUP0303199 A2 HU P0303199A2
Authority
HU
Hungary
Prior art keywords
identification
cell epitopes
immunogenicity
reeduced
new
Prior art date
Application number
HU0303199A
Other languages
English (en)
Inventor
Francis J. Carr
Graham Carter
Anita Hamilton
Tim Jones
Stephen Williams
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of HUP0303199A2 publication Critical patent/HUP0303199A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • C07K16/465—Igs containing CDR-residues from one specie grafted between FR-residues from another with additional modified FR-residues
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7015—Drug-containing film-forming compositions, e.g. spray-on
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C07K16/464—Igs containing CDR-residues from one specie grafted between FR-residues from another
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B15/00—ICT specially adapted for analysing two-dimensional or three-dimensional molecular structures, e.g. structural or functional relations or structure alignment
    • G16B15/20—Protein or domain folding
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16B—BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
    • G16B20/00—ICT specially adapted for functional genomics or proteomics, e.g. genotype-phenotype associations
    • G16B20/50—Mutagenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Biotechnology (AREA)
  • Theoretical Computer Science (AREA)
  • Medical Informatics (AREA)
  • Evolutionary Biology (AREA)
  • Epidemiology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A találmány tárgya egy új megközelítési mód élő szervezetbenimmunválaszt kiváltó T-sejt-epitópok azonosítására. Ennek az újeljárásnak az alkalmazásával olyan biológiai vegyületek állíthatókelő, amelyeknek nincs vagy csökkentett az immunogenitása, amikortalálkoznak egy adott faj immunrendszerével, összehasonlítva areleváns nem módosított entitással. Ily módon a találmány tárgyátképezik új biológiai molekulák, különösen fehérjék és ellenanyagok is,amelyek a találmány szerinti eljárással állíthatók elő. Ó
HU0303199A 2001-02-19 2002-02-18 Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására HUP0303199A2 (hu)

Applications Claiming Priority (12)

Application Number Priority Date Filing Date Title
EP01103954 2001-02-19
EP01105777 2001-03-08
EP01106538 2001-03-15
EP01106536 2001-03-15
EP01107012 2001-03-20
EP01106899 2001-03-20
EP01107568 2001-03-27
EP01110220 2001-04-25
EP01113228 2001-05-30
EP01124965 2001-10-19
EP01126859 2001-11-12
PCT/EP2002/001688 WO2002069232A2 (en) 2001-02-19 2002-02-18 Method for identification of t-cell epitopes and use for preparing molecules with reeduced immunogenicity

Publications (1)

Publication Number Publication Date
HUP0303199A2 true HUP0303199A2 (hu) 2003-12-29

Family

ID=27581535

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0303199A HUP0303199A2 (hu) 2001-02-19 2002-02-18 Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására

Country Status (14)

Country Link
US (1) US7430476B2 (hu)
EP (2) EP1366455B1 (hu)
JP (1) JP4279554B2 (hu)
KR (1) KR100899970B1 (hu)
CN (1) CN100404673C (hu)
AT (1) ATE400030T1 (hu)
AU (1) AU2002256624B2 (hu)
CA (1) CA2438652A1 (hu)
ES (1) ES2309167T3 (hu)
HU (1) HUP0303199A2 (hu)
MX (1) MXPA03007316A (hu)
PL (1) PL362414A1 (hu)
WO (1) WO2002069232A2 (hu)
ZA (1) ZA200307324B (hu)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69824039T2 (de) * 1997-12-08 2005-08-18 Lexigen Pharmaceuticals Corp., Lexington Heterodimäre fusionsproteine zur verwendung für gezielte immuntherapie und allgemeine immunerregung
WO1999052562A2 (en) * 1998-04-15 1999-10-21 Lexigen Pharmaceuticals Corp. Enhancement of antibody-cytokine fusion protein mediated immune responses by co-administration with angiogenesis inhibitor
ATE315787T1 (de) * 1999-05-14 2006-02-15 Univ Mcgill Methoden zur identifizierung von modulatoren wechselwirkender proteine
SK782002A3 (en) 1999-07-21 2003-08-05 Lexigen Pharm Corp FC fusion proteins for enhancing the immunogenicity of protein and peptide antigens
US6617135B1 (en) * 1999-08-09 2003-09-09 Emd Lexigen Research Center Corp. Multiple cytokine protein complexes
MXPA02012734A (es) * 2000-06-29 2003-04-25 Merck Patent Gmbh Mejoramiento de las respuestas inmunes mediadas por la proteina de fusion anticuerpo-citocina, mediante tratamiento combinado con agentes mejoradores de la captacion de inmunocitocina.
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
MXPA03008031A (es) 2001-03-07 2003-12-04 Merck Patent Gmbh Tecnologia de expresion para proteinas que contienen porcion de anticuerpo isotipo hibrida.
US6992174B2 (en) 2001-03-30 2006-01-31 Emd Lexigen Research Center Corp. Reducing the immunogenicity of fusion proteins
CN100503639C (zh) 2001-05-03 2009-06-24 默克专利有限公司 重组肿瘤特异性抗体及其应用
DK200101090A (da) 2001-07-12 2001-08-16 Novozymes As Subtilase variants
WO2003042247A2 (en) * 2001-11-12 2003-05-22 Merck Patent Gmbh Modified anti-tnf alpha antibody
AU2002352162A1 (en) * 2001-11-29 2003-06-10 Merck Patent Gmbh T-cell epitodes in carboxypeptidase g2
WO2003048334A2 (en) 2001-12-04 2003-06-12 Merck Patent Gmbh Immunocytokines with modulated selectivity
CA2476890C (en) * 2002-02-26 2013-07-16 Genencor International, Inc. Subtilisin carlsberg proteins with reduced immunogenicity
US20060019885A1 (en) * 2002-06-11 2006-01-26 Matthew Baker Modified bryodin 1 with reduced immunogenicity
PL372862A1 (en) * 2002-08-09 2005-08-08 Merck Patent Gmbh T-cell epitopes in erythropoietin
AU2003290563A1 (en) * 2002-10-31 2004-05-25 Clf Medical Technology Acceleration Program, Inc. Leptin-related peptides
EP1578397B1 (en) * 2002-11-15 2012-12-26 Genmab A/S Human monoclonal antibodies against cd25
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
CA2527726A1 (en) * 2003-06-02 2004-12-16 Alexion Pharmaceuticals, Inc. De-immunized anti-cd3 antibody
EP1636264A2 (en) * 2003-06-24 2006-03-22 MERCK PATENT GmbH Tumour necrosis factor receptor molecules with reduced immunogenicity
US8147832B2 (en) * 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US20050069521A1 (en) * 2003-08-28 2005-03-31 Emd Lexigen Research Center Corp. Enhancing the circulating half-life of interleukin-2 proteins
US8883147B2 (en) 2004-10-21 2014-11-11 Xencor, Inc. Immunoglobulins insertions, deletions, and substitutions
US8399618B2 (en) 2004-10-21 2013-03-19 Xencor, Inc. Immunoglobulin insertions, deletions, and substitutions
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
AU2004283850C1 (en) 2003-10-16 2011-11-03 Amgen Research (Munich) Gmbh Multispecific deimmunized CD3-binders
BRPI0416141B8 (pt) * 2003-11-01 2021-05-25 Biovation Ltd anticorpo anti-cd52 modificado, composição farmacêutica, vetores de expressão, e método para preparar uma imunoglobulina
EP1697741A4 (en) * 2003-12-04 2008-02-13 Xencor Inc PROCESS FOR PRODUCING PROTEIN VARIANTS WITH INCREASED HOST STRUCTURE CONTENT AND COMPOSITIONS THEREOF
US20060122783A1 (en) * 2004-08-24 2006-06-08 Ishikawa Muriel Y System and method for heightening a humoral immune response
EP1700119B1 (en) * 2003-12-18 2010-02-10 Genencor International, Inc. Beta-lactamase cd4+ t-cell epitopes
JP2008502317A (ja) 2003-12-30 2008-01-31 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング Ｉｌ−７融合タンパク質
WO2005063808A1 (en) * 2003-12-31 2005-07-14 Merck Patent Gmbh Fc-ERYTHROPOIETIN FUSION PROTEIN WITH IMPROVED PHARMACOKINETICS
AU2005206277B2 (en) * 2004-01-22 2011-06-23 Merck Patent Gmbh Anti-cancer antibodies with reduced complement fixation
JP5025460B2 (ja) * 2004-03-19 2012-09-12 メルク パテント ゲーエムベーハー 修飾ブーゲニンタンパク質、サイトトキシン、ならびにそれらの方法および使用
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
SI2471813T1 (sl) 2004-07-15 2015-03-31 Xencor, Inc. Optimirane Fc variante
WO2006029094A2 (en) * 2004-09-02 2006-03-16 Xencor, Inc. Erythropoietin derivatives with altered immunogenicity
US8367805B2 (en) 2004-11-12 2013-02-05 Xencor, Inc. Fc variants with altered binding to FcRn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
AU2005304624B2 (en) 2004-11-12 2010-10-07 Xencor, Inc. Fc variants with altered binding to FcRn
ES2342964T3 (es) * 2004-12-09 2010-07-20 Merck Patent Gmbh Variantes de la interleucina-7 con inmunogenicidad reducida.
ES2417133T3 (es) * 2005-02-03 2013-08-06 Antitope Limited Anticuerpos y proteínas humanas
AU2012209017B2 (en) * 2005-02-03 2014-06-26 Antitope Limited Human antibodies and proteins
DK1931709T3 (en) 2005-10-03 2017-03-13 Xencor Inc FC VARIETIES WITH OPTIMIZED FC RECEPTOR BINDING PROPERTIES
ATE509954T1 (de) 2005-12-30 2011-06-15 Merck Patent Gmbh Anti-cd19-antikörper mit reduzierter immunogenität
ATE555125T1 (de) 2005-12-30 2012-05-15 Merck Patent Gmbh Interleukin-12p40-varianten mit verbesserter stabilität
NZ599035A (en) 2006-01-12 2013-12-20 Alexion Pharma Inc Antibodies to ox-2/cd200 and uses thereof
US20080095756A1 (en) * 2006-09-05 2008-04-24 Biosynexus Incorporated Compositions Comprising Lysostaphin Variants And Methods Of Using The Same
CA2691539C (en) * 2007-06-21 2014-08-26 Angelica Therapeutics, Inc. Modified toxins
JP5341889B2 (ja) 2007-07-17 2013-11-13 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作された抗αＶインテグリンハイブリッド抗体
CA2696339C (en) 2007-08-22 2017-12-19 Probiogen Ag Culture system and method for immunogenicity and immunofunction testing in vitro
EP4269443A3 (en) 2007-12-26 2023-12-27 Xencor, Inc. Fc variants with altered binding to fcrn
WO2009110944A1 (en) 2008-02-29 2009-09-11 Angelica Therapeutics, Inc. Modified toxins
EP2293804B1 (en) 2008-05-29 2013-05-22 Alma Mater Studiorum -Universita' di Bologna Herpes simplex virus (hsv) with modified tropism, uses and process of preparation thereof
CA2742802C (en) 2008-11-10 2019-11-26 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
EP2421896A1 (en) * 2009-04-22 2012-02-29 Merck Patent GmbH Antibody fusion proteins with modified fcrn binding sites
WO2010124259A1 (en) * 2009-04-24 2010-10-28 Centre Hospitalier Universitaire Sainte-Justine Allosteramers for tnf receptors and uses thereof
US8221753B2 (en) 2009-09-30 2012-07-17 Tracon Pharmaceuticals, Inc. Endoglin antibodies
US9493578B2 (en) 2009-09-02 2016-11-15 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
AU2010314798B2 (en) 2009-11-05 2013-10-24 Teva Pharmaceuticals Australia Pty Ltd Treatment of cancer involving mutated KRAS or BRAF genes
MX2012008108A (es) 2010-01-11 2012-10-03 Alexion Pharma Inc Biomarcadores de efectos de inmunomodulacion en seres humanos tratados con anticuerpos anti-cd200.
UA123257C2 (uk) * 2010-02-24 2021-03-10 Іммуноджен, Інк. Виділений поліпептид, що кодує антитіло до рецептора фолієвої кислоти 1
RU2573909C2 (ru) 2010-03-04 2016-01-27 Пфенекс Инк. Способ получения растворимого рекомбинантного белка интерферона без денатурирования
AU2011235210B2 (en) 2010-04-01 2015-07-16 Pfenex Inc. Methods for G-CSF production in a Pseudomonas host cell
WO2011137395A1 (en) 2010-04-30 2011-11-03 Rother Russell P Anti-c5a antibodies and methods for using the antibodies
EA201291328A1 (ru) 2010-06-22 2013-10-30 Дзе Риджентс Оф Дзе Юниверсити Оф Колорадо, Э Боди Корпорейт АНТИТЕЛА К ФРАГМЕНТУ C3d КОМПОНЕНТА КОМПЛЕМЕНТА 3
JP2012041316A (ja) * 2010-08-23 2012-03-01 Akita Univ 新規ペプチド並びに分子シャペロン誘導剤及び抗がん剤
JP6150734B2 (ja) 2011-02-03 2017-06-21 アレクシオン ファーマシューティカルズ， インコーポレイテッド 同種移植片の生存を長期化するための抗ｃｄ２００抗体の使用
PL2672994T3 (pl) 2011-02-11 2018-11-30 Merck Patent Gmbh Przeciwciało przeciwko integrynie alfa-v do leczenia raka prostaty
ES2600616T3 (es) * 2011-03-14 2017-02-10 Phlogo Aps Antagonistas del receptor de la interleucina-1
PT2694106T (pt) 2011-04-01 2018-03-05 Immunogen Inc Métodos para aumentar eficácia de terapia de cancro de folr1
US9073965B2 (en) 2011-04-12 2015-07-07 Temple University—Of the Commonwealth System of Higher Education Adiponectin receptor agonists and methods of use
US9988439B2 (en) 2011-12-23 2018-06-05 Nicholas B. Lydon Immunoglobulins and variants directed against pathogenic microbes
EP2793944A4 (en) 2011-12-23 2015-09-02 Nicholas B Lydon IMMUNOGLOBULINS AND VARIANTS DIRECTED AGAINST PATHOGENIC MICROBES
US20130216530A1 (en) * 2012-02-02 2013-08-22 Exagen Diagnostics, Inc. Methods for optimizing biological response modifier therapy using therapeutic drug monitoring of immunosuppressants
NZ726258A (en) 2012-08-31 2019-07-26 Immunogen Inc Antibodies and uses thereof to detect folate receptor 1
UA115789C2 (uk) 2012-09-05 2017-12-26 Трейкон Фармасутікалз, Інк. Композиція антитіла до cd105 та її застосування
TW202423993A (zh) 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
CA2902905A1 (en) 2013-03-15 2014-09-25 Claude Geoffrey Davis Modified toxins
WO2014180490A1 (en) * 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
SG10201907501QA (en) 2013-08-30 2019-10-30 Immunogen Inc Antibodies and assays for detection of folate receptor 1
WO2015074048A1 (en) * 2013-11-18 2015-05-21 Siscapa Assay Technologies, Inc. Measurement of gamma-carboxylation of proteins
US10627411B2 (en) 2014-03-27 2020-04-21 British Columbia Cancer Agency Branch T-cell epitope identification
US10358636B2 (en) 2014-05-14 2019-07-23 Stealth Biologics, Llc Deimmunized lysostaphin and methods of use
SG11201703406YA (en) 2014-11-05 2017-05-30 Sloan Kettering Inst Cancer Methods of selecting t cell line and donor thereof for adoptive cellular therapy
US9926375B2 (en) 2014-11-12 2018-03-27 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
AU2015346444A1 (en) 2014-11-12 2017-05-04 Tracon Pharmaceuticals, Inc. Anti-endoglin antibodies and uses thereof
KR101669140B1 (ko) * 2015-04-28 2016-10-26 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
US20180247011A1 (en) * 2015-09-01 2018-08-30 The Administrators Of The Tulane Educational Fund A method for cd4+ t-cell epitope prediction using antigen structure
KR102700777B1 (ko) 2015-09-17 2024-08-29 이뮤노젠 아이엔씨 항-folr1 면역접합체를 포함하는 치료제 조합
US10913772B2 (en) * 2016-03-09 2021-02-09 Kine Sciences Co., Ltd. Peptide for preventing or treating inflammatory diseases and use thereof
KR101897122B1 (ko) * 2016-03-09 2018-09-10 주식회사 바이오펩 염증성 질환의 예방 또는 치료용 펩타이드 및 이의 용도
EP3523467A4 (en) * 2016-10-04 2021-10-06 The Council of the Queensland Institute of Medical Research PEPTIDE LIBRARIES AND METHODS OF USE
KR101887577B1 (ko) * 2016-10-19 2018-09-10 (주)케어젠 항비만 및 항당뇨 효능을 갖는 펩타이드 및 이의 용도
GB201618432D0 (en) * 2016-11-01 2016-12-14 Matn Scient Ltd Detection and treatment of demyelinating diseases
WO2019089544A1 (en) 2017-11-01 2019-05-09 Tufts Medical Center, Inc. Bispecific antibody constructs and methods of use
WO2019126536A1 (en) 2017-12-20 2019-06-27 Alexion Pharmaceuticals Inc. Humanized anti-cd200 antibodies and uses thereof
CN109206482B (zh) * 2018-09-30 2021-12-10 福建蓝昊生物科技有限公司 一种抑制消化道炎症的海藻源短肽及其应用
US20220098310A1 (en) 2018-12-06 2022-03-31 Alexion Pharmaceuticals, Inc. Anti-alk2 antibodies and uses thereof
EP3757127A1 (en) * 2019-06-28 2020-12-30 Institute for Research in Biomedicine Deimmunized antibodies binding to alpha-4 integrin and uses thereof
CN110694056B (zh) * 2019-10-25 2023-05-05 四川农业大学 一种fsh抗原及其制备方法以及含有该抗原的fsh疫苗
CA3175852A1 (en) * 2020-04-29 2021-11-04 Onegene Biotechnology Inc. Novel protein conjugate, and use thereof for preventing or treating nonalcoholic steatohepatitis, obesity and diabetes
CN112457399B (zh) * 2020-12-19 2023-09-01 上海佰君生物科技有限公司 一种人免疫球蛋白g的提纯方法
CN112480245B (zh) * 2020-12-19 2023-08-18 上海佰君生物科技有限公司 一种疏水性环状肽配基纯化人免疫球蛋白g的应用
CN116003573A (zh) * 2022-05-30 2023-04-25 四川农业大学 一种卵泡刺激素β亚基活性肽及其应用

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700676A (en) 1984-05-29 1997-12-23 Genencor International Inc. Modified subtilisins having amino acid alterations
US5972682A (en) 1984-05-29 1999-10-26 Genencor International, Inc. Enzymatically active modified subtilisins
US4810643A (en) 1985-08-23 1989-03-07 Kirin- Amgen Inc. Production of pluripotent granulocyte colony-stimulating factor
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DK203187A (da) 1986-04-22 1987-10-23 Immunex Corp Human g-csf proteinekspression
NO176799C (no) 1986-12-23 1995-05-31 Kyowa Hakko Kogyo Kk DNA som koder for et polypeptid, rekombinant plasmid som koder for og kan uttrykke et polypeptid og fremgangsmåte for fremstilling av dette polypeptid
US4914031A (en) 1987-04-10 1990-04-03 Amgen, Inc. Subtilisin analogs
US4904584A (en) 1987-12-23 1990-02-27 Genetics Institute, Inc. Site-specific homogeneous modification of polypeptides
CA1340810C (en) 1988-03-31 1999-11-02 Motoo Yamasaki Polypeptide derivatives of human granulocyte colony stimulating factor
KR900700134A (ko) 1988-04-15 1990-08-11 원본미기재 Il-2 수용체-특이적 키메릭 항체
US5075222A (en) 1988-05-27 1991-12-24 Synergen, Inc. Interleukin-1 inhibitors
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
WO1990008771A1 (en) 1989-01-31 1990-08-09 Rubin Jeffrey S Dna encoding a growth factor specific for epithelial cells
US5166322A (en) 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
AU618675B2 (en) 1989-05-17 1992-01-02 Amgen, Inc. Multiply mutated subtilisins
US6143866A (en) * 1989-07-18 2000-11-07 Amgen, Inc. Tumor necrosis factor (TNF) inhibitor and method for obtaining the same
US5945397A (en) 1989-09-05 1999-08-31 Immunex Corporation Purified p75 (type II) tumor necrosis factor receptor polypeptides
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
US5395760A (en) 1989-09-05 1995-03-07 Immunex Corporation DNA encoding tumor necrosis factor-α and -β receptors
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
EP0438310A1 (en) 1990-01-19 1991-07-24 Merck & Co. Inc. Method for producing recombinant immunoglobuline
US5986070A (en) 1990-04-06 1999-11-16 Amgen Inc. Production of biologically active NGF proteins
GB9107846D0 (en) 1990-04-30 1991-05-29 Ici Plc Polypeptides
DE4014750A1 (de) 1990-05-08 1991-11-14 Boehringer Mannheim Gmbh Muteine des granulozyten-stimulierenden faktors (g-csf)
DE4105480A1 (de) 1991-02-21 1992-08-27 Boehringer Mannheim Gmbh Verbesserte aktivierung von rekombinanten proteinen
ATE196606T1 (de) 1992-11-13 2000-10-15 Idec Pharma Corp Therapeutische verwendung von chimerischen und markierten antikörpern, die gegen ein differenzierung-antigen gerichtet sind, dessen expression auf menschliche b lymphozyt beschränkt ist, für die behandlung von b-zell-lymphoma
WO1995001434A1 (en) 1993-06-29 1995-01-12 Chiron Corporation A truncated keratinocyte growth factor (kgf) having increased biological activity
US5595721A (en) 1993-09-16 1997-01-21 Coulter Pharmaceutical, Inc. Radioimmunotherapy of lymphoma using anti-CD20
US5618714A (en) 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
AU2191795A (en) 1994-03-23 1995-10-09 Alexion Pharmaceuticals, Inc. Method for reducing immune and hemostatic dysfunctions during extracorporeal circulation
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
CU22615A1 (es) * 1994-06-30 2000-02-10 Centro Inmunologia Molecular Procedimiento de obtención de anticuerpos monoclonales murinos menos inmunogénicos. anticuerpos monoclonales obtenidos
US6309853B1 (en) 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US6008328A (en) 1994-10-13 1999-12-28 Amgen Inc. Method for purifying keratinocyte growth factors
US5770577A (en) 1994-11-14 1998-06-23 Amgen Inc. BDNF and NT-3 polypeptides selectively linked to polyethylene glycol
US5869330A (en) 1995-06-05 1999-02-09 Whitehead Institute For Biomedical Research DNA encoding a novel serum protein produced exclusively in adipocytes
US6013256A (en) 1996-09-24 2000-01-11 Protein Design Labs, Inc. Method of preventing acute rejection following solid organ transplantation
NZ514145A (en) 1996-12-20 2003-08-29 Amgen Inc OB fusion protein compositions and methods
US5741772A (en) 1997-02-03 1998-04-21 Amgen Inc. Neurotrophic factor NNT-1
EA002149B1 (ru) 1997-04-28 2001-12-24 Эли Лилли Энд Компани Улучшенные способы приготовления активированного белка с
DE69833755T2 (de) * 1997-05-21 2006-12-28 Biovation Ltd. Verfahren zur herstellung von nicht-immunogenen proteinen
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
JP2002531089A (ja) * 1998-11-30 2002-09-24 イーライ・リリー・アンド・カンパニー 赤血球産生性化合物
JP2002534959A (ja) 1998-12-08 2002-10-22 バイオベーション リミテッド 免疫原性タンパク質の改変方法
KR20020007287A (ko) 1999-01-07 2002-01-26 추후보정 Ｆｃ 융합 단백질로서 항-비만 단백질의 발현 및 이출
BR0008759B1 (pt) * 1999-01-14 2014-03-11 Bolder Biotechnology Inc Métodos para a produção de proteinas contendo resíduos de cisteina livre

Also Published As

Publication number Publication date
CN1493052A (zh) 2004-04-28
WO2002069232A2 (en) 2002-09-06
PL362414A1 (en) 2004-11-02
MXPA03007316A (es) 2003-12-04
ATE400030T1 (de) 2008-07-15
AU2002256624B2 (en) 2007-12-06
WO2002069232A3 (en) 2003-02-13
US7430476B2 (en) 2008-09-30
ES2309167T3 (es) 2008-12-16
KR20030075201A (ko) 2003-09-22
EP1998266A3 (en) 2009-02-11
AU2002256624B8 (en) 2002-09-12
CN100404673C (zh) 2008-07-23
JP4279554B2 (ja) 2009-06-17
JP2004523754A (ja) 2004-08-05
ZA200307324B (en) 2005-02-23
EP1366455B1 (en) 2008-07-02
EP1998266A2 (en) 2008-12-03
CA2438652A1 (en) 2002-09-06
US20040180386A1 (en) 2004-09-16
EP1366455A2 (en) 2003-12-03
KR100899970B1 (ko) 2009-05-28

Similar Documents

Publication Publication Date Title
HUP0303199A2 (hu) Eljárás T-sejt-epitópok azonosítására és csökkentett immunogenitású molekulák előállítására
WO2004063963A3 (en) Novel proteins with altered immunogenicity
UA93855C2 (ru) Вакцина, способствует росту, базирующейся ha нейтрализующем эпитопе
DE60224291D1 (de) System zur antikörperexpression und- synthese
HUP0402048A2 (hu) Eljárás specifikus patogének antigénjeinek azonosítására, izolálására és előállítására
WO2002080851A3 (en) Chimeric vaccines
EP2388271A3 (en) Human Antibodies and Proteins
ATE376559T1 (de) Methoden der verhinderung und behandlung der alzheimer'schen krankheit
WO2003086308A3 (en) Compositions and methods for the diagnosis and treatment of herpes simplex virus infection
WO2003070187A3 (en) Fusion proteins of mycobacterium tuberculosis
HUP0303134A2 (hu) HIV-peptidek, antigének, vakcinakészítmények, immunológiai mérési reagenskészletek és eljárás HIV által indukált antitestek detektálására
WO2020014097A8 (en) Reagents and methods for treating cancer and autoimmune disease
WO2003016464A3 (en) Cancer specific oligosaccharide sequences and use thereof
CY1117746T1 (el) Αντιγονα αιμοφιλου της γριπης και αντιστοιχα θραυσματα dna
WO2003016915A8 (en) Tumor specific oligosaccharide sequences and use thereof
EP1412388A4 (en) HUMANIZED ANTIBODIES DERIVED FROM DD-3B6 / 22, SPECIFIC OF THE FIBRIN D-DIMER FRAGMENT
ATE372350T1 (de) Methode zur produktion oder verstärkung einer t- zell antwort gegen eine zielzelle durch verwendung eines komplexes aus einem hla klasse i moleküls und einer vorrichtung zum anheften
EP1297147B8 (en) Compositions for the diagnosis and treatment of herpes simplex virus infection
WO2005026192A3 (en) Hpv cd8+ t-cell epitopes
WO2002077012A3 (en) Human papilloma virus immunoreative peptides
ATE345354T1 (de) Methode zur identifizierung von helicobacter antigenen
YU68602A (sh) Monoklonska antitela na humani ldl receptor, njihova produkcija i korišćenje
SE9903534L (sv) Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning
DK1406927T3 (da) Glycopeptider, fremstilling og anvendelse deraf til diagnosticering eller terapeutisk behandling af dissemineret sklerose
DK1146889T3 (da) Identifikation af specifikke differentielt udtrykte mycobakterielle antigener og medicinsk anvendelse af Mycobakteriumproteinerne Rv0068 og Rv3407

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees